VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Marburg virus DNA vaccine MARV GP encoding GP
Vaccine Information
  • Vaccine Name: Marburg virus DNA vaccine MARV GP encoding GP
  • Target Pathogen: Marburg Virus
  • Target Disease: Hemorrhagic fever
  • Vaccine Ontology ID: VO_0004387
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse, rabbit, guinea pig
  • GP from Marburg virus Ravn gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pWRG7077 expressed MARV Musoke GP in challenge study with macaques (Riemenschneider et al., 2003).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000346
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Macaque Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: All of the MARV GP DNA-vaccinated guinea pigs developed antibodies to MARV (Riemenschneider et al., 2003).
  • Efficacy: In both studies (two different strains - Musoke and Ravn), two of three GP DNA-vaccinated monkeys were aviremic on the days assayed, and survived challenge, while one monkey in each study developed viremia levels similar to those of control monkeys and died. These results indicate that DNA vaccination alone is able to offer immunity to nonhuman primates, but suggest that the protective effect is near the threshold of vaccine efficacy (Riemenschneider et al., 2003).
References
Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144 ].